Cargando…

Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus

BACKGROUND: CF-301 is a novel, recombinantly-produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class to enter clinical development in the US for the treatment of bacteremia including endocarditis due to S.aureus. This study evaluated the in vitro activity of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sauve, Karen, Jandourek, Alena, Cassino, Cara, Schuch, Raymond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631334/ http://dx.doi.org/10.1093/ofid/ofx163.908

Ejemplares similares

1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
por: Anastasiou, Diane, et al.
Publicado: (2018)

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
por: Anastasiou, Diane, et al.
Publicado: (2019)

Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
por: Schuch, Raymond, et al.
Publicado: (2014)

712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires
por: Karau, Melissa J, et al.
Publicado: (2019)

671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Xiong, Yan, et al.
Publicado: (2019)

Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
por: Oh, Jun, et al.
Publicado: (2017)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection
por: Swift, Steven M., et al.
Publicado: (2021)

Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase
por: Vila-Farres, Xavier, et al.
Publicado: (2023)

1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2020)

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections
por: Souche, Aubin, et al.
Publicado: (2022)

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires
por: Karau, Melissa J., et al.
Publicado: (2023)

The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
por: Oh, Jun, et al.
Publicado: (2023)

Trans-Cinnamaldehyde Exhibits Synergy with Conventional Antibiotic against Methicillin-Resistant Staphylococcus aureus
por: Wang, Shu, et al.
Publicado: (2021)

1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus (S. aureus) Bloodstream Infections (Bacteremia) Including Endocarditis
por: Ghahramani, Parviz, et al.
Publicado: (2020)

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection
por: Ferry, Tristan, et al.
Publicado: (2021)

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance
por: Schuch, Raymond, et al.
Publicado: (2022)

LB3. Exebacase (EXE) Reduced Length of Stay and 30-Day Readmission Rates for US Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Including Endocarditis Compared with Standard of Care Antibiotics (SoC) Alone in a Phase 2 Study
por: Cassino, Cara, et al.
Publicado: (2019)

STAPHYLOCOCCUS AUREUS ENTEROTOXINS IN PEOPLE WITH CYSTIC FIBROSIS (CF)
por: Wen, Hongjie, et al.
Publicado: (2020)

Antibacterial synergy between rosmarinic acid and antibiotics against methicillin-resistant Staphylococcus aureus
por: Ekambaram, Sanmuga Priya, et al.
Publicado: (2016)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
por: Cassino, Cara, et al.
Publicado: (2021)

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
por: Oh, Jun T., et al.
Publicado: (2021)

Bacillus subtilis revives conventional antibiotics against Staphylococcus aureus osteomyelitis
por: Zhang, Fan, et al.
Publicado: (2021)

In Vitro Synergy of Pongamia pinnata Extract in Combination with Antibiotics for Inhibiting and Killing Methicillin-Resistant Staphylococcus aureus
por: Su, Po-An, et al.
Publicado: (2020)

Proteomic profiling of lysine acetylation and succinylation in Staphylococcus aureus
por: Xia, Jingyan, et al.
Publicado: (2022)

301. Penicillin Versus Cefazolin or Anti-staphylococcal Penicillins for Penicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aldhaeefi, Mohammed, et al.
Publicado: (2020)

Demonstration of the role of cell wall homeostasis in Staphylococcus aureus growth and the action of bactericidal antibiotics
por: Salamaga, Bartłomiej, et al.
Publicado: (2021)

Mechanism of Synergy between Piceatannol and Ciprofloxacin against Staphylococcus aureus
por: Shi, Mengyan, et al.
Publicado: (2022)

The Mechanism of Bisdemethoxycurcumin Enhances Conventional Antibiotics against Methicillin-Resistant Staphylococcus aureus
por: Wang, Shu, et al.
Publicado: (2020)

Resensitisation of Methicillin-Resistant Staphylococcus aureus to Conventional Antibiotics in the Presence of an Engineered Enzybiotic
por: Manoharadas, Salim, et al.
Publicado: (2023)

Lysine Inhibits Hemolytic Activity of Staphylococcus aureus and Its Application in Food Model Contaminated with Staphylococcus aureus
por: Wan, Yangli, et al.
Publicado: (2022)

Double-disk synergy test for detection of synergistic effect between antibiotics against nosocomial strains of staphylococcus aureus
por: Soltani, Rasool, et al.
Publicado: (2012)

301 Risk of Methicillin-Resistant Staphylococcus aureus Infection in Patients with Intermittent vs Persistent Nares Colonization
por: Vigil, Daniel I., et al.
Publicado: (2014)

Antibacterial activity and synergy of antibiotics with sanguisorbigenin isolated from Sanguisorba officinalis L. against methicillin‐resistant Staphylococcus aureus
por: Wang, S., et al.
Publicado: (2021)

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
por: Vazquez, Jose A., et al.
Publicado: (2015)

Combination of Alpha-Melanocyte Stimulating Hormone with Conventional Antibiotics against Methicillin Resistant Staphylococcus aureus
por: Singh, Madhuri, et al.
Publicado: (2013)

Effects of Luteolin and Quercetin in Combination with Some Conventional Antibiotics against Methicillin-Resistant Staphylococcus aureus
por: Usman Amin, Muhammad, et al.
Publicado: (2016)

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
por: Lee, Ji-Young, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_pcngsnag5s0gmcbkc4dd592vbk